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AbstrAct
Whereas clinical trials of cancer drugs have methodological standards and conventional primary endpoints, these 
are not necessarily applicable to the clinical development of loco-regional treatments and new medical devices. The 
current challenge is to generate high-level clinical evidence for loco-regional treatments to define the benefits for 
patients. In this article, we argue that, to generate convincing evidence of clinical efficacy and safety, the collective 
coherence of the entire data package is often more important than the primary endpoint of one clinical trial. We also 
propose that, when a comprehensive clinical data package is not feasible, limited clinical data can be supplemented 
with other types of evidence. Emerging life science companies often define the “valley of death” after securing initial 
investment to translate an early medical device concept to a development stage that is attractive to funders. Unfor-
tunately for this industry, there is a second “valley of death” if the focus and goal is only regulatory approval, to the 
neglect of clinical acceptance and reimbursement. For the emerging specialism of interventional oncology, it is critical 
to plan a clear line of sight for each new medical device to avoid the valleys of death and to demonstrate the clinical 
benefit. Increased international guidance to establish realistic yet convincing standards in this area may avoid attrition 
of potentially beneficial devices and therapeutic procedures in the valleys of death.
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the current issues
Clinical trials of cancer drugs have methodological stan-
dards and conventional primary endpoints, particularly 
overall survival and progression-free survival. These stan-
dards are based on the industry’s experience of a line of sight 
for a new drug, with an understanding of the regulatory 
challenges that will be encountered to achieve the licensing 
goal. Clinicians play a key role in defining new regulatory 
standards and justifying clinically relevant endpoints.1–4
The standards and endpoints for new drugs are not neces-
sarily applicable to the clinical development of loco- 
regional treatments and new medical devices. Clinicians in 
the disciplines of surgical oncology, radiation oncology and 
interventional oncology (IO) recognize that the current 
challenge for these specialties is to generate high-level 
clinical evidence for loco-regional treatments to define the 
benefits for patients.2,3,5 There is a need for standards that 
are proportionate, reasonable and pragmatic, and for clin-
ical studies with realistic and patient-centred endpoints. 
Consistent with a recent article on the licensing of new 
drugs,1 we argue that, to generate convincing evidence 
of clinical efficacy and safety to regulators, the collec-
tive coherence of the entire data package is often more 
important than the primary endpoint of one clinical trial. 
Furthermore, when a comprehensive clinical data package 
is not feasible, limited clinical data can be supplemented 
with other types of evidence (e.g. from clinical registries or 
from observational studies).
An example in point is selective internal radiotherapy using 
yttrium-90 microspheres. One manufacturer of this class 
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Figure 1. The valleys of death for new medical devices. Life 
science companies often define the “valley of death” as secur-
ing the initial investment to translate an early medical device 
concept to a clinical development stage that is attractive to 
funders. There is also a second “valley of death” potentially 
following regulatory approval, if sufficient clinical evidence is 
not demonstrated for clinical acceptance, cost-effectiveness 
and reimbursement. 
of medical device invested in long-term, phase III, randomized 
controlled trials with conventional medical oncology endpoints 
(overall survival and progression-free survival) as primary 
endpoints for studies in patients with metastatic colorectal 
cancer or hepatocellular carcinoma.6,7  Although these studies 
did not reach their primary endpoints, they demonstrated the 
importance of considering the entire package of clinical data 
when discussing the safety and efficacy of a medical device with 
patients (e.g. control of liver disease for a liver-directed therapy 
when added to standard therapy, and quality of life following 
a liver-directed therapy as an alternative to systemic therapy). 
An example of a medical device with FDA premarket approval 
which has not been adopted widely is the AspireAssist weight-
loss device8 This device, which uses a surgically-placed tube to 
drain a portion of the stomach contents after every meal, is an 
example of an approved device for which health professionals 
may be waiting for more evidence to be published before advo-
cating the technology more widely.
A recent trend in IO has been to divert resources away from 
clinical trials of medical devices towards the collection of more 
heterogeneous “real world” data in clinical registries.2,9 This can 
be justified, in some cases, by the realization that formal clinical 
trial pathways can take a decade or more to address endpoints 
such as overall survival. During this long timescale, the tech-
nology being studied or the standard of care for that disease may 
have evolved, rendering the study obsolete. Assuming the quality 
of the data being collected in a “real world” setting is acceptable, 
we wish to emphasize that registry data can generally augment 
but not substitute for high-quality clinical trial data to establish 
safety and efficacy. Registries may address specific uncertainties 
in a timely and pragmatic way when randomized controlled clin-
ical trials are not feasible.
Diverting funds away from clinical trial development is, unfor-
tunately, only the tip of the iceberg in the current threat to the 
medical device industry. Emerging life science companies often 
define the “valley of death” after securing initial investment to 
translate an early medical device concept to a development stage 
that is attractive to funders.10 Unfortunately for this industry, 
there is a second “valley of death” if the focus and goal is only 
regulatory approval, to the neglect of clinical acceptance and 
reimbursement (Figure 1). In Europe, medical devices require a 
conformité européenne (CE) mark. Having obtained a CE mark, 
companies are often unable to find users for the product due to 
lack of clinical evidence supporting its clinical benefit or cost 
effectiveness. In the USA, the US Food and Drug Administra-
tion (FDA)’s 510(k) submission for “equivalence” to a predicate 
device (one that has been cleared by the FDA or marketed before 
1976) does not mandate clinical data. Devices with higher risk 
require a premarket application, which does require clinical data, 
but generally less than submissions for new cancer drugs.
The current situation is similar to the fundamental problem 
described by Sung et al11 over a decade ago when they described 
the blocks to translation of basic science discoveries in to high 
quality clinical studies due to high costs, lack of funding, regula-
tory burdens, fragmented infrastructure, incompatible databases 
and a shortage of qualified investigators and willing participants. 
Although specific to the USA, some of the recommendations 
made by Sung et al are broadly relevant to the issues described in 
this article for interventional oncology; some of the suggestions 
are incorporated in to our recommendations (see below).
Payers and other public or private organizations may also take an 
active role to generate evidence to inform treatment and reim-
bursement decisions. The US Centers for Medicare and Medicaid 
Services have recently implemented “Merit-based Payment 
Systems” and “Alternate Payment Models”, which may empower 
outcomes analyses for new and old medical technologies.
recommenDAtions
In order to address some of these issues, we recommend that 
there should be a recognition that the outcomes of IO clinical 
trials depend on factors such as the manual abilities of the oper-
ator, the number of cases done per year by a centre, differences 
in practice in different centres, dependency on sophisticated 
medical devices with complex learning, diversity of medical 
devices used in different centres and rapid technological evolu-
tion of techniques and devices. Providers of interventional 
oncology should be encouraged to ensure education of their staff 
to apply clinical evidence to their own clinical practice and deci-
sion making. Standards to generate high-level clinical evidence 
should be similar in aims to those accepted for new drugs in 
oncology. However, they should acknowledge the different 
regulations, challenges, specificities and flexibility needed for 
IO trials. Regulations should be standardized and streamlined, 
allowing information to be accessed by both investigators and 
the general public. Standards must be proportionate, reasonable, 
pragmatic, and they should help the clinical studies to achieve 
realistic and clinically important objectives. Financial conflicts 
of interests among investigators, institutions and healthcare 
providers should be transparent.
Overall survival is still the gold standard as a primary endpoint 
for drug studies, but in practice it is often not the ideal choice 
for IO studies. Reasons for this include the long survival of 
patients, evolution of the technology during that timescale, and 
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diverse, sequential treatments making it very difficult to asso-
ciate overall survival with one specific treatment.6 The choice 
of primary endpoint needs therefore to consider reliable and 
readily measurable intermediate efficacy endpoints. Collections 
of endpoints such as overall response rate, tumour response, 
depth of response, time to progression, organ-specific progres-
sion-free survival, might be good candidates alongside quality of 
life, activities of daily living and other patient-reported outcomes, 
and health economics assessments.
Finally, to the users of the devices, i.e. the physicians and the 
multidisciplinary teams, we advise them to explicitly ask the 
manufacturers for evidence of efficacy before they consider 
changing their clinical practice. Providers of healthcare and 
professional societies should promote and support a research 
culture that mandates a certain level of clinical evidence for all 
the health services being provided.
concLusions
For the emerging specialism of interventional oncology, it is 
critical to plan a clear line of sight for each new medical device 
to avoid the “valleys of death” and to demonstrate the clinical 
benefit. Increased international guidance to establish realistic 
yet convincing standards in this area may avoid attrition of 
potentially beneficial devices and therapeutic procedures in the 
“valleys of death”.
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